Login to Your Account

Biogen snaps up Pfizer schizophrenia asset for $75M plus milestones

By Michael Fitzhugh
Staff Writer

Tuesday, March 13, 2018

Biogen Inc. has moved to buy a midstage neuropsychiatric drug from Pfizer Inc. for $75 million up front, up to $515 million in potential milestones, and tiered royalties in the low to midteens.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription